Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Total Current Liabilities (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Total Current Liabilities for 6 consecutive years, with $20.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 53.88% to $20.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.9 million, a 53.88% decrease, with the full-year FY2025 number at $20.9 million, down 53.88% from a year prior.
  • Total Current Liabilities was $20.9 million for Q4 2025 at Lexicon Pharmaceuticals, down from $21.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $110.7 million in Q1 2025 to a low of $20.4 million in Q1 2023.
  • A 3-year average of $35.9 million and a median of $29.7 million in 2023 define the central range for Total Current Liabilities.
  • Biggest YoY gain for Total Current Liabilities was 373.07% in 2025; the steepest drop was 53.88% in 2025.
  • Lexicon Pharmaceuticals' Total Current Liabilities stood at $31.5 million in 2023, then skyrocketed by 43.43% to $45.2 million in 2024, then plummeted by 53.88% to $20.9 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Total Current Liabilities are $20.9 million (Q4 2025), $21.7 million (Q3 2025), and $34.8 million (Q2 2025).